Table 9.

Neuroimaging.

Reference	Population	Treatment	Diagnosis	Response criteria	Follow-up	Predictor	Risk of bias
Cheng et al. (2015)	353 AD patients	Donepezil, galantamine, rivastigmine	Clinical (probable AD, NINCDS-ADRDA)	Longer TMSE decline-free survival (Survival analysis, using TMSE decline of 3+ points as endpoint)	Survival analysis, median 46.6 months	Lower total MTA score and older age	Low
Connelly et al. (2005a,b)	140 AD patients (160 enrolled)	Donepezil, galantamine, rivastigmine	Clinical (probable AD, NINCDS-ADRDA)	At least two of gain of 2+ points on MMSE, improvement of the combined score IALD and social behavior subscales of NOSGER (or maintenance of maximum score), positive global change as defined as a tripartite agreement amongst doctor, subject, and carer (global impression) at 6 months	3 years (actually 6 months)	Less medial temporal lobe atrophy at baseline	Moderate
Um et al. (2017)	64 AD patients	Donepezil	Clinical (probable AD, NINCDS-ADRDA)	2+ points improvement in MMSE	24 weeks	Higher left hippocampal total volume and left CA1 volume (no cut-offs provided)	Moderate
Csernansky et al. (2005)	39 AD patients (37 completed the study)	Donepezil	Clinical (NINCDS-ADRDA)—doesn't state whether it's probable or possible	Rate of change in ADAS-Cog (primary outcome); CDR, MMSE, NPI (secondary outcome)—Fiala et al. (1998) and Krstic et al. (2012)	2 years	Smaller hippocampal volumes associated with deformation of the lateral and inferomedial surface (inward deformation of the hippocampal surface in proximity to the CA1 subfield and the subiculum) are negative predictor	High
Graff-Radford et al. (2012)	54 DLB patients	Donepezil, galantamine, rivastigmine	Clinical (probable DLB, McKeith et al., 2004)	Reliable change in Dementia Rating Scale: reliable improvement with 9+ points increase in <15 months and 10+ >15 months, reliable decline 6+ decrease in <15 months, and 7+ decrease >15 months, stability in between	1 year	Larger hippocampal volume	Low
Teipel et al. (2016)	215 suspected prodromal AD patients	Donepezil	Clinical (progressive hippocampal amnestic syndrome: free recall ≤ 17 or total recall <40 on FCSRT)	Change in ADAS-Cog-MCI, CDR, TMT-A/B, CVLT	12 months + 6 months OLE	Higher hippocampal volume	Some concerns—Low
Visser et al. (2005)	121 AD patients	Rivastigmine	Clinical (probable AD, NINCDS-ADRDA, and DSM-IV)	2+ points improvement on MMSE or 4+ points improvement on ADAS-Cog	26 weeks	Absence of medial temporal atrophy (Giacobini et al., 2022) in patients receiving low dose of rivastigmine; medial temporal lobe atrophy in general is not a predictor	Low
Salib Tony Sheridan Mark Allington (2001)	59 AD patients	Donepezil 5 mg	Clinical (NINCDS-ADRDA, not stated if possible included)	Unclear: “improvement or cognitive stability,” but non-response is defined as deterioration with MMSE <10 during the study period—probably means that non-responders are those who had to discontinue treatment	2 years	Lower bicaudate span and bicaudate ratio	High